Stephen B. Spurgin

Stephen B. Spurgin

Auto-generated profile, based on publicly available information

Stephen B. Spurgin

Department of Molecular Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, Texas, USA 75390

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2012 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CKChristine M Kusminski
Christine M Kusminski
WHWilliam L Holland
William L Holland
Kai SunKai Sun
Kai Sun
JPJiyoung Park
Jiyoung Park
SSStephen B Spurgin
Stephen B Spurgin
PSPhilipp E Scherer
Philipp E Scherer

1 February 2016 in Cell Metabolism
Verified
Journal Article
Closed access
LVLavanya Vishvanath
Lavanya Vishvanath
KMKaren A. MacPherson
Karen A. MacPherson
CHChelsea Hepler
Chelsea Hepler
QWQiong A Wang
Qiong A Wang
MSMengle Shao
Mengle Shao
RGRana K. Gupta
Rana K. Gupta

1 June 2016 in Cell Metabolism
Verified
Journal Article
Closed access
MSMengle Shao
Mengle Shao
JIJeff Ishibashi
Jeff Ishibashi
CKChristine M. Kusminski
Christine M. Kusminski
QWQiong A Wang
Qiong A Wang
CHChelsea Hepler
Chelsea Hepler
RGRana K. Gupta
Rana K. Gupta

1 July 2014 in Molecular Metabolism
Verified
Journal Article
Open access
Kai SunKai Sun
Kai Sun
CKChristine M. Kusminski
Christine M. Kusminski
KLKate Luby-Phelps
Kate Luby-Phelps
SSStephen B. Spurgin
Stephen B. Spurgin
YAYu An
Yu An
PSPhilipp E Scherer
Philipp E Scherer
We recently reported that local overexpression of VEGF-A in white adipose tissue (WAT) protects against diet-induced obesity and metabolic dysfunction. The observation that VEGF-A induces a "brown adipose tissue (BAT)-like" phenotype in WAT prompted us to further explore the direct function of VEGF-A in BAT. We utilized a doxycycline (Dox)-inducible, brown adipocyte-specific VEGF-A transgenic overexpression model to assess direct effects of VEGF-A in BAT in vivo. We observed that BAT-specific VEGF-A expression increases vascularization and up-regulates expression of both UCP1 and PGC-1α in BAT. As a result, the transgenic mice show increased thermogenesis during chronic cold exposure. In diet-induced obese mice, introducing VEGF-A locally in BAT rescues capillary rarefaction, ameliorates brown adipocyte dysfunction, and improves deleterious effects on glucose and lipid metabolism caused by a high-fat diet challenge. These results demonstrate a direct positive role of VEGF-A in the activation and expansion of BAT.

16 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
GSGabriele G. Schiattarella
Gabriele G. Schiattarella
FAFrancisco Altamirano
Francisco Altamirano
SKSoo Young Kim
Soo Young Kim
DTDan Tong
Dan Tong
AFAnwarul Ferdous
Anwarul Ferdous
JHJoseph A. Hill
Joseph A. Hill
Heart failure with preserved ejection fraction (HFpEF) is now the dominant form of heart failure and one for which no efficacious therapies exist. Obesity and lipid mishandling greatly contribute to HFpEF. However, molecular mechanism(s) governing metabolic alterations and perturbations in lipid homeostasis in HFpEF are largely unknown. Here, we report that cardiomyocyte steatosis in HFpEF is coupled with increases in the activity of the transcription factor FoxO1 (Forkhead box protein O1). FoxO1 depletion, as well as over-expression of the Xbp1s (spliced form of the X-box-binding protein 1) arm of the UPR (unfolded protein response) in cardiomyocytes each ameliorates the HFpEF phenotype in mice and reduces myocardial lipid accumulation. Mechanistically, forced expression of Xbp1s in cardiomyocytes triggers ubiquitination and proteasomal degradation of FoxO1 which occurs, in large part, through activation of the E3 ubiquitin ligase STUB1 (STIP1 homology and U-box-containing protein 1) a novel and direct transcriptional target of Xbp1s. Our findings uncover the Xbp1s-FoxO1 axis as a pivotal mechanism in the pathogenesis of cardiometabolic HFpEF and unveil previously unrecognized mechanisms whereby the UPR governs metabolic alterations in cardiomyocytes.

8 March 2016 in Diabetes
Verified
Journal Article
Open access
PDF file
CKChristine M. Kusminski
Christine M. Kusminski
SCShiuhwei Chen
Shiuhwei Chen
RYRisheng Ye
Risheng Ye
KSKai Sun
Kai Sun
QWQiong A Wang
Qiong A Wang
PSPhilipp E Scherer
Philipp E Scherer
Mitochondrial metabolism plays an integral role in glucose-stimulated insulin secretion (GSIS) in β-cells. In addition, the diabetogenic role of glucagon released from α-cells plays a major role in the etiology of both type 1 and type 2 diabetes because unopposed hyperglucagonemia is a pertinent contributor to diabetic hyperglycemia. Titrating expression levels of the mitochondrial protein mitoNEET is a powerful approach to fine-tune mitochondrial capacity of cells. Mechanistically, β-cell–specific mitoNEET induction causes hyperglycemia and glucose intolerance due to activation of a Parkin-dependent mitophagic pathway, leading to the formation of vacuoles and uniquely structured mitophagosomes. Induction of mitoNEET in α-cells leads to fasting-induced hypoglycemia and hypersecretion of insulin during GSIS. MitoNEET-challenged α-cells exert potent antiapoptotic effects on β-cells and prevent cellular dysfunction associated with mitoNEET overexpression in β-cells. These observations identify that reduced mitochondrial function in α-cells exerts potently protective effects on β-cells, preserving β-cell viability and mass.